Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avalo Therapeutics (AVTX) granted stock options to three new employees on November 18, 2026, as an inducement to join the company. The options cover 52,000 common shares in total at an exercise price of $6.70 per share, equal to the stock’s closing price on the grant date.
25% of the options vest one year after each employee’s start date, and the rest vest monthly over the following 36 months, subject to continued service through each vesting date. The compensation committee approved the grants under Nasdaq Listing Rule 5635(c)(4), and the options are subject to Avalo’s 2025 Inducement Award Plan and related award agreements.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options on 52,000 common shares at $6.70 per share could dilute existing shareholders if exercised.
Key Figures
- Options granted
- 52,000 shares
- Aggregate awards to three new employees
- Exercise price
- $6.70 per share
- Equal to the closing price on the grant date
- Initial vesting
- 25%
- On the applicable employee’s one-year employment anniversary
- Remaining vesting period
- 36 months
- Remaining shares vest monthly, subject to continued service
Historical Context
-
Prior grants used the same plan and 25%-then-monthly 36-month service-based vesting schedule.
-
Prior grants used the same plan and 25%-then-monthly 36-month service-based vesting schedule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nonstatutory stock options financial
nasdaq listing rule 5635(c)(4) regulatory
mab medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 52,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Options were granted on November 18, 2026, and have an exercise price of
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiries
Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.